Pharmaceutical manufacturing: people on the move

The International Society of Pharmaceutical Engineers (ISPE)​ has appointed Douglas Ellsworth​ as its new International Regulatory Affairs Advisor. In this capacity Ellsworth will collaborate with regulatory authorities around the world, update ISPE Members on significant regulatory developments and initiate new projects. Ellsworth is leaving his post as district director of the US Food and Drug Administration's (FDA) New Jersey District, where he had responsibility for investigational and enforcement activities in the region. Prior to holding this post Ellsworth was director of the Division of Manufacturing and Product Quality in the Center for Drug Evaluation and Research (CDER). Ellsworth has worked at the FDA since 1974, holding posts with a wide range of scientific and managerial responsibilities. Bruce Palsulich​ has rejoined Relsys International​ as chief innovation & strategy officer. This gives Palsulich responsibility for Relsys' future product development and direction. Palsulich worked for Relsys when the company first began and was the original developer of the Argus Safety suite. When he left the company in 2004 Palsulich was vice president of product development. Since then he has pursued personal entrepreneurial initiatives. Relsys is pleased to welcome Palsulich back, believing his knowledge and understanding of risk management in the pharmaceutical industry will held drive the company forward. The changes at Boehringer Ingelheim​ are continuing unabated with Dr Alessandro Banchi​ leaving his post as chairman of the board of managing directors after more than 35 years at the company. His successor is the current vice-chairman of the board of managing directors, Dr Andreas Barner​. Barner's current role on the board is to be filled by Tjeenk Willink​. ​Dr Hans-Jürgen Leuchs​, the longest-serving member of the board of managing directors, has also announced he is to retire. He will be replaced as the board member responsible for operations and human resources by Dr Wolfram Carius​. GmbH​, an active pharmaceutical ingredient (API) audit service provider blue inspection body, has appointed Prof Werner Fresenius​ as chairman of its advisory board. The newly constituted board also includes Dr Hans-Joachim Janhsen​ and Dr Eckhard Milsmann​ who will advise the management of the blue inspection body on all scientific and technical aspects of the worldwide auditing of APIs.